Barbed Reposition Pharyngoplasty in Patients Complaining of Unilevel Palatal Snoring
Launched by AZ DELTA · Dec 7, 2022
Trial Information
Current as of January 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • single-level retro-palatal collapse observed during drug-induced sleep endoscopy (DISE)
- Exclusion Criteria:
- • OSAS defined as having an obstructive AHI (OAHI) ≥ 30
- • Obese patients with a body mass index (BMI) ≥ 30 kg/m².
- • Patients with multilevel airway collapse observed during DISE
- • Patients younger than 18 years old.
About Az Delta
Az Delta is a leading clinical trial sponsor dedicated to advancing medical research and innovative therapies. With a focus on enhancing patient outcomes, the organization specializes in the design and management of clinical studies across various therapeutic areas. Az Delta is committed to upholding the highest standards of ethical practices and regulatory compliance, ensuring the integrity and reliability of trial results. Collaborating with healthcare professionals, research institutions, and industry partners, Az Delta strives to accelerate the development of groundbreaking treatments that address unmet medical needs, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roeselare, , Belgium
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials